Dapagliflozin & Vildagliptin Sustained Release Tablets – DAPILA VG 10/100

Dapagliflozin & Vildagliptin Sustained Release Tablets – A powerful dual combination for optimized diabetes management.

DAPILA VG 10/100: The Dual combination of Dapagliflozin 10mg + Vildagliptin 100mg SR Tablets is a bilayered tablet that combines Vildagliptin and Dapagliflozin for an effective management strategy for type 2 diabetes. Vildagliptin works by inhibiting the DPP-4 enzyme, thereby enhancing insulin secretion and lowering glucagon levels in a glucose-dependent manner. Dapagliflozin aids in glycemic control by preventing glucose reabsorption in the kidneys, promoting its elimination in the urine. Together, they provide a comprehensive approach to managing blood sugar levels, enhancing both fasting and postprandial control.

Recommended By Specialists:
Endocrinologists: It should be mainly used to prefer this combination to treat the disease associated with Preferred in patients needing both postprandial and fasting glucose control, along with weight management
General Physicians: It is mainly used to prefer this combination to treat the disease for moderate to uncontrolled Type 2 diabetes
Cardiologists: It is mainly used to prefer this combination to treat the disease associated with the treatment of diabetic patients with cardiovascular risk factors, due to Dapagliflozin’s heart-protective properties

Key Benefits of Dapagliflozin & Vildagliptin Sustained Release Tablets – DAPILA VG 10/100
Dual Mechanism of Action: Vildagliptin, a DPP-4 inhibitor, increases incretin levels to stimulate insulin release and decrease glucagon secretion, while Dapagliflozin, an SGLT2 inhibitor, promotes glucose excretion through the kidneys, effectively lowering blood sugar levels.
Sustained Release Technology: Vildagliptin’s sustained-release (SR) formulation ensures prolonged action throughout the day, providing stable blood glucose control with reduced fluctuations.
Weight Neutral and Cardiovascular Benefits: This combination is associated with minimal weight gain and may offer cardiovascular protection, addressing common concerns among patients with type 2 diabetes.

INDICATIONS:
Type 2 Diabetes Mellitus
Inadequate glycemic control
Monotherapy resistance